Home>>Signaling Pathways>> Others>> Others>>Pirozadil

Pirozadil Sale

(Synonyms: 吡扎地尔) 目录号 : GC31415

Pirozadil is a hypolipidemic agent.

Pirozadil Chemical Structure

Cas No.:54110-25-7

规格 价格 库存 购买数量
10mM (in 1mL DMSO)
¥1,554.00
现货
5mg
¥1,339.00
现货
10mg
¥2,142.00
现货
25mg
¥4,373.00
现货

电话:400-920-5774 Email: sales@glpbio.cn

Customer Reviews

Based on customer reviews.

Sample solution is provided at 25 µL, 10mM.

产品文档

Quality Control & SDS

View current batch:

产品描述

Pirozadil is a hypolipidemic agent.

[1] Roca J, et al. Methods Find Exp Clin Pharmacol. 1981 Nov-Dec;3(6):397-401.

Chemical Properties

Cas No. 54110-25-7 SDF
别名 吡扎地尔
Canonical SMILES O=C(OCC1=CC=CC(COC(C2=CC(OC)=C(OC)C(OC)=C2)=O)=N1)C3=CC(OC)=C(OC)C(OC)=C3
分子式 C27H29NO10 分子量 527.52
溶解度 DMSO : 62.5 mg/mL (118.48 mM);Water : < 0.1 mg/mL (insoluble) 储存条件 Store at -20°C
General tips 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。
为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。
Shipping Condition 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。

溶解性数据

制备储备液
1 mg 5 mg 10 mg
1 mM 1.8957 mL 9.4783 mL 18.9566 mL
5 mM 0.3791 mL 1.8957 mL 3.7913 mL
10 mM 0.1896 mL 0.9478 mL 1.8957 mL
  • 摩尔浓度计算器

  • 稀释计算器

  • 分子量计算器

质量
=
浓度
x
体积
x
分子量
 
 
 
*在配置溶液时,请务必参考产品标签上、MSDS / COA(可在Glpbio的产品页面获得)批次特异的分子量使用本工具。

计算

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % saline
计算重置

Research Update

Effect of pirozadil on lipids, lipoproteins and apolipoproteins in Japanese with type IIa hyperlipoproteinemia

Pirozadil (pyridine 2,6-dimethanol-bis(3,4,5-trimethoxybenzoate), Pemix) was administered for 16 weeks at a dose of 1.5 or 2.0 g/d to 15 adults with Type IIa hyperlipidemia. All patients had achieved a stable weight and were given a diet before treatment. Plasma lipids, lipoproteins and apolipoproteins were measured at 4-week intervals. Pirozadil reduced the mean total cholesterol (TC) level from 291.0 mg/dl to 260.8 mg/dl in 16 weeks (p less than 0.05). The mean percentage decrease was 8.5% in week 16. Low density lipoprotein (LDL)-cholesterol and apolipoprotein B (apoB) decreased 9.7% and 8.5%, respectively, in week 16. A decrease of more than 10% in TC, representing a decrease of more than 30 mg/dl, was observed in 12 of the 15 patients. These 12 patients, who were regarded as responders, showed mean decreases in the levels of TC, LDL-cholesterol and apoB of 13.7%, 10.4% and 11.7%, respectively, but no significant change in the level of high density lipoprotein (HDL)-cholesterol or serum triglycerides. Eight of 11 patients in the lower dose group (1.5 g/d) and all 4 patients who had obtained the higher dose (2.0 g/d) were responders. Suspected side effects of pirozadil were edema, numbness of the extremities and palpitation. The results obtained suggest the beneficial effect of pirozadil on serum lipids in patients with Type IIa hyperlipoproteinemia.

[Antiplatelet action of pirozadil]

[Single-blind study of the efficacy of pirozadil versus alufibrate in the treatment of primary hyperlipoproteinemias]

Pirozadil and alufibrate are compared by a single-blind study over two groups 20 patients with primary hyperlipoproteinemia. Pirozadil seems more effective as a cholesterol-lowering agent. There were no adverse reactions. We conclude that pirozadil can be a valuable agent in preventing atherosclerotic disease.

[Clinical pharmacology of pirozadil]

[Clinical evaluation of pirozadil, administered continuously over four and a half years, in patients with hyperlipoproteinemia type IIa]

With the goal to evaluate the long term efficacy and tolerance of pirozadil, 20 patients with hypercholesterolemia (type II a hyperlipoproteinemia) received this drug for 4.5 years. Lipidic parameters and the appearance of subjective manifestations related to the drug were periodically controlled. The triglyceride concentration (34%), total cholesterol (24%) and LDL-cholesterol (47%) decreased after 6 months of treatment with 1.5 to 2 g/day of pirozadil. These changes were more manifest during the second semester of therapy and did not show important oscolations in subsequent controls. Adverse effects, indicating the withdrawal of the drug were not encountered. Three patients had minor and transient epigastralgias. Taken as a whole, these results reinforce the usefulness of pirozadil in treating patients with hypercholesterolemias.